PARPi combinations against HR-proficient tumors.

Slides:

Advertisements

Similar presentations

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Advertisements

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Dose-escalation patient response.

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin. Strategies for differential inhibition of mTORC1 and mTORC2 with rapamycin.

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

PARP Inhibition: The New Frontier in Recurrent Ovarian Cancer

MAPK pathway inhibitors.

Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart summarising the process for the identification of eligible studies.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.

Volume 114, Issue 2, Pages (February 1998)

Figure 4 Possible combination therapies CDK4/6 inhibitors

The PI3K/Akt signalling and its activation in cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Figure 2 from Sancho et al.

Evolving Concepts in the Management of Head and Neck Cancers

Potential clinical actionability.

Fig. 2. Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and MEKi Mutant KRAS mediates resistance to PARPi and sensitivity to PARPi and.

Maintenance Therapy in Advanced Ovarian Cancer

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Mechanisms of PARPi resistance in HR-deficient cells.

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive to MEK inhibition. Merlin-deficient RAS-mutant cells and murine PDTCs are more sensitive.

HIV Drug to Aid Melanoma Therapies?

Volume 147, Issue 3, Pages (December 2017)

(A) Progression-free survival in the hormone receptor-negative cohort patients treated with PARPi versus those treated with mono chemotherapy (controls).

Objective response rate in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Mutant BRAF Melanomas—Dependence and Resistance

Pro-inflammatory biomarkers in decompensated and stable HFpEF patients

ALK resistance mutations predict for sensitivity to lorlatinib in patient-derived cell line models of acquired resistance to ceritinib. ALK resistance.

Changes in tumor sizes, CA-125, serum ceruloplasmin, and copper levels in 5 patients with platinum-resistant high-grade epithelial ovarian cancer who received.

(A) Progression-free survival in patients with BRCA-mutated HER2-negative breast cancer treated with PARPi versus those treated with monochemotherapy (controls).

Schematic representation of the therapeutic strategies that can be applied to target ARF876L. Schematic representation of the therapeutic strategies that.

A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue),

EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. EHop-016 and INK128 treatment of myxofibrosarcoma xenografts in NSG mice. A,

Matriptase-2 inhibited breast tumor development in vivo.

Correlation between serum visfatin concentrations and the clinical stage (A) and tumor size (B, C) of HCCs. A and B, the correlations were determined by.

Clinical outcomes resulting from inhibition of tumor-intrinsic and myeloid NF-κB activation in melanoma chemotherapy. Clinical outcomes resulting from.

Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

Curcumin enhances effects of bortezomib to inhibit angiogenesis in multiple myeloma tumor samples. Curcumin enhances effects of bortezomib to inhibit angiogenesis.

Discovered and replicated positive correlation between miR-193b

Targeting HR via CDK inhibition resensitizes recurrent cultures to temozolomide (TMZ). Targeting HR via CDK inhibition resensitizes recurrent cultures.

Cells lacking CDK6 kinase function are required to mutate p53.

Replication stress inhibition synergizes with DNA damaging agents in human cells. Replication stress inhibition synergizes with DNA damaging agents in.

Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level.

Representative images demonstrating LOH in breast cancer patients’ paired BM aspirate and primary tumors (T) at D14S62, D14S51, and D8S321, respectively.

High-throughput drug screen (HTDS) reveals ARS1620 and PI3K pathway inhibitors synergies and a heterogeneous pattern of RTK synergies. High-throughput.

Combined inhibition of coamplified RTKs is required for response.

Possible outcomes of therapeutic treatments using the spiral model.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Pros and cons for neoadjuvant immunotherapy.

Frequently mutated genes in colorectal cancer.

Putative molecular pathways showing how GSK3β regulates the fate of tumor cells (survival, proliferation, or apoptosis) and influences their sensitivity.

RhuαVEGF and rhuαVEGF/paclitaxel mediated growth inhibition in an androgen-independent prostate cancer xenograft model. rhuαVEGF and rhuαVEGF/paclitaxel.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Schematic representation of signaling pathways associated with cannabinoid receptor activation induced by its agonists. Schematic representation of signaling.

DHT-dependent phase of prostate cancer.

Anti–PD-1/PD-L1–mediated acquired resistance is dependent on CD38-generated adenosine in the tumor microenvironment. Anti–PD-1/PD-L1–mediated acquired.

Strategies for personalized precision immunotherapy.

Blocking αvβ3/galectin-3 binding with GCS-100 selectively kills KRAS-addicted lung cancer cells. Blocking αvβ3/galectin-3 binding with GCS-100 selectively.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

NSD2-mediated methylation of PTEN at K349 dictates cellular sensitivity to DNA-damaging agents. NSD2-mediated methylation of PTEN at K349 dictates cellular.

Cooperation of the FA and BRCA1/2 proteins in a common ICL repair pathway. Cooperation of the FA and BRCA1/2 proteins in a common ICL repair pathway. Stalling.

WEE1 inhibition followed by TRAIL treatment results in apoptotic cell death in MB231 cells. WEE1 inhibition followed by TRAIL treatment results in apoptotic.

Genotype-specific combinatorial drug sensitivities in melanoma.

Presentation transcript:

PARPi combinations against HR-proficient tumors. PARPi combinations against HR-proficient tumors. Rationale behind use of specific PARPi combinations as a strategy against HR-proficient tumors. Specifically, use of agents that inhibit HR, such as CDK1 or HSP90 inhibitors may render HR-proficient tumors into HR-deficient tumors and thus sensitize them to platinum or PARPis. The proposed mechanism of HR suppression and the clinical status of these PARPi combinations are presented in the right panel. Panagiotis A. Konstantinopoulos et al. Cancer Discov 2015;5:1137-1154 ©2015 by American Association for Cancer Research